A maker of ultra-sensitive blood tests and tissue-imaging tools for biology research and diagnostics. Its Simoa platform detects single protein molecules in blood, powering tests like LucentAD Complete for Alzheimer's disease, while its PhenoCycler spatial biology systems map proteins inside intact tissue. Founded in 2007 by scientist David Walt, whose lab invented the single-molecule array technology, the company began life as Digital Genomics before renaming itself Quanterix. Simoa is short for "single molecule array," and the firm grew further by acquiring spatial-biology pioneer Akoya Biosciences in 2025.
A $26.9M goodwill impairment drove Quanterix's Q2 net loss to $48.9M, and the company pushed its cash flow breakeven target to 2027.
A $26.9 million on the Akoya acquisition turned the quarter. rose 34% to $32.9 million, entirely from Akoya, but fell to 38.5% and the net loss widened to $48.9 million as legacy product demand weakened. The company now expects to reach in 2027, a year later than planned, with $93.6 million in cash and marketable securities on hand.
Key takeaways
A $26.9 million non-cash tied to the Akoya Biosciences acquisition was recorded in the quarter, driving the net loss to $48.9 million from $30.0 million a year ago.
Total rose 34% to $32.9 million, with Akoya contributing $9.3 million in product revenue and $3.0 million in service revenue, while legacy Quanterix product revenue fell $2.7 million on weaker academic and pharmaceutical demand.
declined 2.3 percentage points to 38.5%, as cost of goods sold and services rose 40%, including $2.9 million in of acquired from Akoya.
Section summaries
Management's Discussion and Analysis
Q2 revenue rose 34% to $32.9M on Akoya, but a $26.9M goodwill impairment drove net loss to $48.9M.
⌄
Total Q2 rose 34% to $32.9M, with Akoya adding $9.3M of product revenue and $3.0M of service revenue, while legacy Quanterix product revenue fell $2.7M on weaker academic and pharma demand.
R&D expense fell 14% to $7.8 million and SG&A fell 10% to $27.4 million, helped by lower acquisition costs, restructuring-related headcount reductions, and the absence of a non-recurring contingent payment from the prior year.
Cash, equivalents, and marketable securities totaled $93.6 million at quarter-end, and management pushed its target from year-end 2026 to 2027.
The company submitted a to the FDA in January 2026 for a multi-analyte Alzheimer's blood test and reported new Anthem coverage for its LucentAD Complete test starting July 1, 2026.
What changed
The target, previously set for the second half of 2026, was pushed to 2027, a shift from the Q1 FY2026 filing where management stated it expected to reach breakeven in the second half of 2026.
The Simoa ONE launch, previously targeted for year-end 2025 and absent from the Q1 FY2026 filing, was again not mentioned in this quarter's discussion, leaving its status unclear.
Legacy product continued to decline, falling $2.7 million after a 19% drop in Q1 FY2026, with management citing weaker academic and pharmaceutical demand — an acceleration of the trend flagged in earlier filings.
The $26.9 million on the Akoya acquisition is a new charge, distinct from the $6.4 million recorded in Q2 FY2025 on a different reporting unit, and reflects a reassessment of the Akoya business's carrying value.
What to watch
Whether the $93.6 million in cash and marketable securities is sufficient to fund operations to the newly targeted 2027 , given the $5.1 million operating cash outflow this quarter.
Whether legacy product stabilizes or continues to decline, and whether reduced academic and pharmaceutical demand becomes a persistent beyond the current quarter.
The status of the Simoa ONE launch, which was previously targeted for year-end 2025 but has not been mentioned in the last two quarterly filings.
Whether the 510(k) submission for the multi-analyte Alzheimer's blood test leads to FDA clearance and whether the new Anthem coverage for LucentAD Complete begins generating material diagnostic .
declined to 39% from 41% as total cost of goods sold and services rose 40%, including $2.9M of acquired intangible from Akoya.
A $26.9M tied to the Akoya acquisition drove Q2 net loss to $48.9M, up from $30.0M a year earlier.
R&D expense fell 14% to $7.8M and SG&A fell 10% to $27.4M, helped by lower acquisition costs, restructuring-related headcount reductions, and a non-recurring 2025 contingent payment.
Cash, equivalents, and marketable securities totaled $93.6M at June 30, 2026; the company pushed its target from year-end 2026 to 2027.
The company submitted a 510(k) to the FDA in January 2026 for a multi-analyte Alzheimer's blood test and reported new Anthem coverage for LucentAD Complete starting July 1, 2026.
Quantitative and Qualitative Disclosures About Market Risk
As of June 30, 2026, there have been no material changes to the market risk information from those described in the section titled "Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk" included in our 2025 Form 10-K.
⌄
As of June 30, 2026, there have been no material changes to the market risk information from those described in the section titled "Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk" included in our 2025 Form 10-K.
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings and threats of litigation consisting of intellectual property, contractual, employment, and other matters. While the outcome of any such actions or proceedings…
⌄
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings and threats of litigation consisting of intellectual property, contractual, employment, and other matters. While the outcome of any such actions or proceedings cannot be predicted with certainty, as of June 30, 2026, we were not party to any legal proceedings, the outcome of which would be expected to have a material adverse effect on our financial condition or results of operations. Regardless of any outcome, litigation can have a material adverse effect on us due to defense and settlement costs, diversion of management resources, and other factors.
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition, results of operations, or the price of our common stock. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully co…
⌄
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition, results of operations, or the price of our common stock. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors set forth in the section titled "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K"), as filed with the SEC on March 2, 2026. These risk factors are not the only risks we face. Additional risks and uncertainties not currently known to us or that we deem to be not material also may adversely affect our business, financial condition, and results of operations.
As of the date of this Quarterly Report on Form 10-Q, there were no material changes to the risk factors described in our Form 10-K.